The 2015 abstract categories, along with their related subcategories and subclassifications, follow. When you use the Abstract Submission System, these options will be available for your selection. Authors are asked to choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the Annual Meeting 2015. Please note that these abstract categories may or may not be used as Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification.
ABSTRACT CATEGORIES

TB02 Stem Cell Biology/Cancer Stem Cells/Developmental Oncobiology
Adult stem cells
Cancer stem cells
Developmental pathways in cancer
Embryonic stem cells
Stem cell markers
Stem cell-based therapies
Other

TB03 Tumor Adhesion
Cell adhesion and extracellular matrix
Cell-cell adhesion
Drug resistance
In vitro models of tumor adhesion
Other

TB04 Tumor Metastasis
Biomarkers of tumor metastasis
CTC/DTC detection
Epithelial/mesenchymal transition (EMT and MET)
Expression profiling of tumor progression and metastasis
Imaging of tumor progression and metastasis
Metastasis suppressor genes
Metastasis-promoting genes
Premetastatic niche
Therapeutic metastasis prevention
Other

TB05 Angiogenesis, Vasculogenesis, Microcirculation, and Cellular Microenvironment
Angiogenesis inhibitors
Antiangiogenic kinase inhibitors
Endothelial cell functions in vitro and in vivo
Host-tumor interactions
Metronomic therapy
Molecular mechanisms of angiogenesis
Novel pro- and antiangiogenic factors
Resistance to angiogenesis inhibitors
Tumor microcirculation and the microenvironment
VEGF/VEGF receptors
Other

TB06 Tumor Microenvironment
Chemokines in the microenvironment
Drug targets in the microenvironment
Epigenetic responses to the microenvironment
Extracellular matrix and integrins
Gene expression in the microenvironment
Immune cells in the tumor microenvironment
Immunity and the microenvironment
Inflammatory cells as regulators of tumor growth
Microbiome
Organ-specific microenvironments
Proteases and inhibitors in the microenvironment
Tumor dormancy
Tumor/stromal interactions
Tumor-immune system interactions
Other

TB07 In Vivo Imaging
(See also CH05 Imaging Agents and Radiotherapeutics)
Advanced nanotechnology and imaging
Application of imaging technology to the clinic
Imaging in animal models
Imaging of molecular and cellular events in the tumor microenvironment
Imaging of molecular and cellular events in tumors and tumor cells
Imaging the immune response
Imaging tumor metabolism
New targets for imaging
Other

TB08 Pediatric Cancer - Basic Science
(See also CL02: Pediatric Cancer - Clinical Investigations.)
Developmental signaling pathways in childhood cancer
Epigenomics of childhood cancer
Pediatric cancer genomics
Preclinical models of childhood cancer
Other

TB09 Radiation Biology
(See also CH08: Radiation Oncology; ET09: Preclinical Radiotherapeutics)
Cell cycle and apoptosis in radiation responses
Cytokines in radiation response
DNA damage and repair and mutagenesis
Molecular modulators of radiation response
Oncogenes and tumor suppressor genes in radiation responses
Photobiology/photodynamic therapy
Radiation resistance
Radiation-activated signaling pathways
Radiation-induced biochemical alterations
Radiation-induced gene expression
Radioprotectors and radiosensitizers
Other

TB10 Migration and Invasion
Actin cytoskeleton
Genes that regulate migration and invasion
Invasion
Microtubules
Migration
Models of migration and invasion
Other

CG Carcinogenesis
CG01 Carcinogenesis - Chemical, Viral, and Radiation
Animal and in vitro models for carcinogenesis
Chemical carcinogenesis
DNA damage and repair
Environmental carcinogenesis
Hormonal carcinogenesis
Host-virus interactions
Immune suppression and carcinogenesis
Molecular carcinogenesis
Mutagenesis
Other

Predictive assays for carcinogenicity
Premalignant lesions (intrarepithelial neoplasia)
Radiation carcinogenesis
Reactive oxygen studies/oxidative stress
Signal transduction
Toxicology
Tumor promotion
Viral-induced transformation
Other

CH Cancer Chemistry
CH01 Drug Discovery and Design
Basic and applied nanotechnology and therapeutics
Chemoinformatics, in silico screening, and computational methods
Drug delivery
Drug design
High-throughput screening (assays and libraries)
Lead identification
Lead optimization
Natural products
Synthesis, metabolism, and disposition
Other

CH02 Structural and Chemical Biology
Chemical genetics, genomics, and glycomics
Nanotechnology in chemical biology
Small molecule, protein, and nucleic acid interactions
Target identification, small molecule probes, and libraries
X-ray and NMR structures
Other

CH03 Proteomics, Metabolomics, and Biological Mass Spectrometry
Biological mass spectrometry and systems biology
Proteomics and biomarker discovery
Proteomics and signaling networks
Other

CH04 Chemical Aspects of Carcinogenesis
Carcinogen metabolism and disposition
Nucleic acid damage
Other

CH05 Imaging Agents and Radiotherapeutics
(See also TB07: In Vivo Imaging)
Imaging agents and radiotherapeutics
Other

CH06 Drug Delivery
Basic and applied nanotechnology and therapeutics
Other

CL Clinical Research
(not including clinical trials; see also the Clinical Trials Sections)
CL01 Translational Research – Molecular Biology in the Clinic
Cytogenetics and clinical molecular genetics
Functional and molecular imaging

Abstract Submission Deadline: December 3, 2014
AACR ANNUAL MEETING 2015
Laboratory correlates/new agents that target signal transduction pathways, growth factors, and cell cycle progression
Molecular classification of tumors
Molecular diagnostics
Tumor staging: Correlation of clinical and molecular markers
Other

CL02 Pediatric Cancer – Clinical Investigations
(See also TB08: Pediatric Cancer - Basic Science)
Behavioral science in childhood cancer
Childhood cancer drug development
Immunotherapeutic approaches to childhood cancer
Survivorship research
Therapeutic advances in pediatric oncology
Translational studies in children
Other

CL03 Clinical Research in the Elderly
Aging, immunity, and cancer
Outcomes research
Pharmacologic considerations
Other

CL04 Clinical Research in Minorities and Medically Underserved Populations
Aging, immunity, and cancer
Outcomes research
Pharmacologic considerations
Other

CL05 Biostatistics in Clinical Trials
Biostatistical methods in translational studies
Comparative effectiveness research and cost-effective studies
Design and analysis of clinical trials
New study designs: Theory, methodology, and modeling
Other

CL06 Ethics in Clinical Trials
Ethics in Clinical Trials
Other

CL07 Clinical Immunology/Biological Therapy
(See IM02: Cancer Immunotherapy, Preclinical and Clinical)

CL08 Radiation Oncology
(See TB09: Radiation Biology; ET09: Preclinical Radiotherapeutics)
Clinical radiotherapeutic studies
Modification of radiation sensitivity
Radiation resistance
Radiation-induced late effects/second cancers
Other

CL09 Clinical Endocrinology
(See also EN01: Molecular and Preclinical Endocrinology; EN02: Clinical Endocrinology)

CL10 Supportive Care and Survivorship Research
Biology of cell and tissue damage
Late effects and second cancers
Outcomes research
Psycho-oncology
Supportive care, palliation, and pain management
Translational survivorship research
Other

CL11 Molecular Biomarkers for Diagnosis, Prognosis, and Prediction
Biomarkers predictive of therapeutic benefit
Diagnostic/early detection biomarkers
Liquid biopsies (including circulating free DNA, circulating tumor cells, exosomes, ncRNA in blood, etc.)
Prognostic/metastasis biomarkers
Other

CL12 Regulatory Science and Policy
Biomarker validation
Clinical trial accrual
Clinical trial design
Codevelopment of investigational agents
Codevelopment of therapeutics and diagnostics
Quantitative data modeling
Retrospective analyses
Safety biomarkers and assays
Toxicology models
Other

CT Clinical Trials
CT01 Phase I Adult Clinical Trials
(See also ET05: Pharmacology, Pharmacogenetics, and Pharmacogenomics)

CT02 Phase II Adult Clinical Trials

CT03 Phase III Adult Clinical Trials

CT04 Phase I, II, or III Clinical Trials in Pediatric Cancer

CT05 Phase I, II, or III Clinical Trials in the Elderly

CT06 Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations

CT07 Clinical Trials Using Radiation
Phase I, II, or III clinical trials using radiation alone
Phase I, II, or III clinical trials using radiation in combination with other agents

CT08 Clinical Trials in Progress
Phase I clinical trials
Phase II clinical trials
Phase III clinical trials

EN Endocrinology
EN01 Molecular and Preclinical Endocrinology
(See also EN02: Clinical Endocrinology)
Growth factors and receptors
Hormone signaling and inhibitors
Nuclear receptors: Structure and function
Preclinical studies of endocrine-related cancers
Receptors and signal transduction
Retinoids and receptors
Steroid hormone receptors
Other

EN02 Clinical Endocrinology
(See also EN01: Molecular and Preclinical Endocrinology)
Endocrine-related cancers (breast, ectopic hormone-related cancers, gynecological cancers, prostate/genitourinary cancers)
Hormone receptors and diagnosis/prognosis
Hormone synthesis, metabolism, and inhibitors
Neuroendocrine and other endocrine factors
Retinoid-based cancer therapy
Other

EP Epidemiology
EP01 Epidemiology (Including Genetic and Molecular Epidemiology)
Biomarkers of endogenous or exogenous exposures, early detection, and biologic effects
Biomarkers of prognosis
Descriptive epidemiology, covering cancer incidence, mortality, clusters, and trends
Diets, alcohol, tobacco use, and other lifestyle risk factors
Environmental and occupational risk factors
Familial and hereditary cancers
Functional studies of genetic variants (methods and bioinformatics approaches in genomic studies)
Gene–gene and gene-environment interactions
Genome-wide association studies/post-GWAS studies
Health disparities research
Health services and comparative effectiveness research
Infection and immune factors
Intermediate biomarkers for chemoprevention
Next-generation sequencing in epidemiology studies
(whole genome, exome, targeted or fine-mapping)
Pathway and candidate gene studies of risk or prognosis
Pharmacoeconomics
Prenatal and tumor markers
Primary and secondary intervention studies
Psychosocial and behavioral epidemiology
Risk prediction models for incidence, prognosis, and/or mortality
Screening and early detection
Statistical and epidemiological methodology
Survivorship research
Other

ET Experimental and Molecular Therapeutics
ET01 Drug Discovery
Antibody technologies
Biological modulators of the therapeutic index
Combination chemotherapy
Differentiation therapy
New targets
Novel assay technology
Novel drug delivery systems
The tumor microenvironment in innovative cancer drug development
Other
ABSTRACT CATEGORIES

ET02  Mechanisms of Drug Action
Cell cycle mechanisms of anticancer drug action
Cellular responses to anticancer drugs
Interactions of new agents with radiation
Role of the microenvironment in therapeutic response
Other

ET03  New Molecular Targets
Cell death pathways and treatment
Identification of molecular targets
Modulation of DNA repair
Molecular classification of tumors for diagnostics,
prognostics, and therapeutic outcomes
New in vitro and in vivo models for targets
Other

ET04  Drug Resistance
Biochemistry of membrane metabolism and transport
Drug resistance in molecular targeted therapies
Drug transport and metabolism
Glutathione metabolism
Non-P-glycoprotein multidrug resistance
Novel mechanisms
Regulation of gene expression in drug resistance
Reversal of drug resistance
Other

ET05  Pharmacology, Pharmacogenetics, and Pharmacogenomics
(See also CT01: Phase I Adult Clinical Trials)
Cellular pharmacology
Molecular pharmacology
Pharmacogenetics and therapeutic response
Pharmacokinetics and pharmacodynamics
Preclinical toxicology
Other

ET06  Small Molecule Therapeutic Agents
Alkylating agents
Antifolates
DNA-reactive agents
Epigenetic targets
HDAC and methyltransferase inhibitors
Novel antitumor agents
Novel targets and pathways
PI3K/AKT inhibitors
Platinum complexes
Proteasome inhibitors
Topoisomerases
Tubulin agents
Tyrosine kinase and phosphatase inhibitors
Other

ET07  Biological Therapeutic Agents
(See also IM02: Cancer Immunotherapy, Preclinical and Clinical)
Antireceptors
Apoptosis: Therapeutic manipulation
Growth factor receptors and other surface antigens as
targets for therapy
Oncogenes, tumor suppressor genes, and gene products
as targets for therapy
Protein kinases and phosphatases as targets for therapy

The role of microenvironment in therapeutic response
Other

ET08  Gene and Vector-Based Therapy
Antisense molecules
Gene therapy and radiation studies
Immune modulators
Nonbiological delivery systems
Vector systems and targeting strategies
Other

ET09  Preclinical Radiotherapeutics
(See also TB09: Radiation Biology; CL08: Radiation Oncology)
Combination therapies/organ site-specific phase I, II,
and III clinical trials
Modification of radiation sensitivity
Molecular targets of a selected response
Normal tissue/cellular stress responses to radiation
Radiation-induced late effects/second cancers
Radioprotectors and radiosensitizers
Other

IM  Immunology

IM01  Tumor Immunobiology
Adaptive immunity in tumors
Epigenetic regulation of tumor immunity
Immune cells in the tumor microenvironment including
stroma
Inflammation and cancer: Metastasis
Inflammation and cancer: Tumor initiation and
progression
Innate immunity to tumors
Microbiome, inflammation, and cancer
Novel animal models
Oncogenic pathway-mediated regulation of inflammation
and tumor immunity
Tumor antigenicity/processing and presentation
Tumor-induced immune suppression: Extrinsic factors
Tumor-induced immune suppression: Intrinsic factors
Other

IM02  Cancer Immunotherapy, Preclinical and Clinical
Adaptive cell therapy
Immune checkpoints
Immune mechanisms invoked by other therapies
including chemotherapy
Immune mechanisms invoked by radiation therapy
Immune monitoring/clinical correlates
Immune response to therapies
Immunomodulatory agents and interventions
Inflammation, immunity, and cancer: Epidemiology
Inflammation, immunity, and cancer: Other
Modifiers of the tumor microenvironment
Therapeutic antibodies, including engineered antibodies
Vaccines (oncolytic and prophylactic)
Other

PR  Prevention Research

PR01  Preclinical Prevention Studies
Animal models in prevention
Biological and biochemical mechanisms in prevention
Biomarkers and intervention studies
Cellular models
Chemaprevention studies
Diet and cancer
Microbiome and cancer prevention
Molecular markers in prevention research
Molecular targets for cancer prevention and development
of new agents
Other

PR02  Clinical Prevention Studies
Application of molecular pathology in clinical prevention
Biomarkers and intervention studies
Cancer surveillance and screening studies
Chemoprevention clinical trials
Genetic markers as surrogate endpoints in prevention
trials
Genomics and proteomics in cancer risk and response
assessment
Metastasis prevention as adjuvant therapy
Microbiome and cancer prevention
Prevention and treatment of premalignant lesions
(intraepithelial neoplasia)
Prevention of second cancers
Prophylactic surgery in cancer prevention
Recruitment of special populations in clinical prevention
trials
Translational models of chemoprevention
Other

PR03  Behavioral and Social Science in Cancer Prevention Research
Behavioral science and cancer prevention
Cancer communication and decision making
Diffusion and dissemination
Genetic testing and counseling
Health disparities research
Health economics, policy, and outcomes
Obesity, diet, physical activity, and energy balance
Prevention behaviors (sun exposure, other)
Quality of life/late effects/survivorship
Screening and early detection
Tobacco: Use, effects, prevention, and cessation
Other